GIP / GLP-1 / Glucagon Tri-Agonist
What is Retatrutide?
Retatrutide (LY3437943) is an investigational triple receptor agonist that simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. It represents one of the most advanced molecules currently in clinical research for metabolic conditions.
Mechanism of Action
By simultaneously activating GIP, GLP-1, and glucagon receptors, Retatrutide produces a coordinated multi-pathway effect. GLP-1 and GIP receptor activation suppresses appetite and improves insulin secretion, while glucagon receptor activity promotes energy expenditure and fat oxidation. This tri-agonist approach is designed to produce greater metabolic benefit than dual or single-receptor agents.
Research Applications
Phase 2 clinical trials have evaluated Retatrutide in adults with obesity, demonstrating significant reductions in body weight over 24–48 weeks. Researchers are also investigating its potential in type 2 diabetes management, non-alcoholic steatohepatitis (NASH), and related cardiometabolic conditions.
Current Research Status
Retatrutide is currently undergoing Phase 3 clinical trials. It has not yet received approval from any regulatory body for therapeutic use. All research is conducted under clinical trial protocols by qualified investigators.
Storage & Handling
For research purposes, lyophilised Retatrutide should be stored at 2–8°C and protected from light. Once reconstituted, it should be used promptly or stored according to laboratory protocols.
Research Disclaimer: Retatrutide is a research compound. It has not been approved by any regulatory body for therapeutic use in humans. This content is for educational and scientific research purposes only.